Delcath Systems to Host Fourth Quarter and Full Year 2021 Results
March 15, 2022 16:30 ET
|
Delcath Systems, Inc.
NEW YORK, March 15, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
Delcath Systems to Present at the 34th Annual Roth Conference
March 10, 2022 09:00 ET
|
Delcath Systems, Inc.
NEW YORK, March 10, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will...
Delcath Systems Achieves Medical Device Regulation Certification for CHEMOSAT® in Europe
March 02, 2022 16:01 ET
|
Delcath Systems, Inc.
NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is...
Delcath Systems Announces Move to a Direct Sales & Marketing Model for CHEMOSAT®
February 22, 2022 09:00 ET
|
Delcath Systems, Inc.
NEW YORK, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
Delcath Systems to Present at Upcoming Virtual Investor Conferences
February 10, 2022 16:30 ET
|
Delcath Systems, Inc.
NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
Delcath Appoints Anthony Dias as its new Vice President of Finance; Inducement Grant Reported
February 07, 2022 16:01 ET
|
Delcath Systems, Inc.
NEW YORK, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
Results of Single Center Study on Delcath’s CHEMOSAT® Hepatic Delivery System Published in Melanoma Research
February 03, 2022 16:30 ET
|
Delcath Systems, Inc.
Retrospective Study by University Hospital Southampton in metastatic uveal melanoma (mUM) patients with liver dominant disease shows hepatic disease control rate of 88.9%, hepatic response rate of...
Global Aptamers Market accounted for US$ 205.40 million in 2020 and is estimated to be US$ 985.44 million by 2030 and is anticipated to register a CAGR of 16.90% - By PMI
February 01, 2022 09:57 ET
|
PMI
Covina, Feb. 01, 2022 (GLOBE NEWSWIRE) -- The report "Global Aptamers Market, By Type (Nucleic Acid and Peptides (DNA-Based Aptamers, RNA-Based Aptamers, and XNA-Based Aptamers)), By Application...
David Hoffman Joins Delcath Systems, Inc. as General Counsel and Corporate Secretary
January 25, 2022 16:01 ET
|
Delcath Systems, Inc.
NEW YORK, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today...
Bile Duct Cancer Drugs Market Report Up to 2031: Visiongain Research Inc
January 12, 2022 10:00 ET
|
Visiongain Ltd
Visiongain has published a new report on Bile Duct Cancer Drugs Market Report to 2031. Profiles of Leading Bile Duct Cancer Drugs Market players, Regional and Leading National Market Analysis. PLUS,...